SFA-002

N/A

Report date: 2025/03/11 20:00:09
NME

Base Information

Drug NameSFA-002
Drug Alias NameSFA-002SFA002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor α inhibitorsInterleukin-23 inhibitorsInterleukin-10 inhibitors +[6] 
TargetsTumor necrosis factor αInterleukin-23Interleukin-10 +[6] 
Therapy Area/IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSFA Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSFA Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A